PMID- 36433671 OWN - NLM STAT- MEDLINE DCOM- 20230417 LR - 20230418 IS - 1468-3083 (Electronic) IS - 0926-9959 (Linking) VI - 37 IP - 5 DP - 2023 May TI - Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study. PG - 884-893 LID - 10.1111/jdv.18778 [doi] AB - BACKGROUND: Choosing the adequate systemic treatment for melanoma is driven by clinical parameters and personal preferences. OBJECTIVE: Evaluation of the impact of disease and treatment on the daily life of patients receiving systemic therapy for melanoma. METHODS: A German-wide, cross-sectional comparative study was conducted at 13 specialized skin cancer centres from 08/2020 to 03/2021. A questionnaire was distributed to assess patients' perception of disease and symptoms, the impact of their current treatment on quality of life (QOL) and activities, adverse events (AEs), therapeutic visits, as well as believe in and satisfaction with their current systemic melanoma treatment. Patient-reported outcomes (PROs) were rated on a continuous numerical rating scale or selected from a given list. RESULTS: Four hundred and fourteen patients with systemic melanoma therapy were included. 359 (87%) received immune checkpoint inhibition (ICI) and 55 (13%) targeted therapy (TT). About 1/3 of patients were adjuvantly treated, the remaining because of unresectable/metastatic melanoma. In subgroup analyses, only in the adjuvant setting, TT patients reported a significant decrease in their treatment associated QOL compared to patients with ICI (p = 0.02). Patients with TT were 1.9 times more likely to report AEs than patients with ICI, a difference being significant just for the adjuvant setting (p = 0.01). ICI treatment intervals differed significantly between adjuvant and unresectable/metastatic setting (p = 0.04), though all patients, regardless of their specific ICI drug, evaluated their treatment frequency as adequate. TT patients with dabrafenib/trametinib (n = 37) or encorafenib/binimetinib (n = 15) did not differ regarding the strain of daily pill intake. Patients older than 63 years rated various PROs better than younger patients. CONCLUSIONS: Patients evaluated their treatment mainly positively. ICI might be preferred over TT regarding QOL and patient-reported AEs in the adjuvant setting. Older melanoma patients appeared to be less impacted by their disease and more satisfied with their treatment. CI - (c) 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. FAU - Thiem, Alexander AU - Thiem A AUID- ORCID: 0000-0001-9504-4281 AD - Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany. FAU - Mashhadiakbar, Pegah AU - Mashhadiakbar P AD - Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany. FAU - Cussigh, Christiane AU - Cussigh C AD - Department of Dermatology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany. FAU - Hassel, Jessica C AU - Hassel JC AD - Department of Dermatology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany. FAU - Grimmelmann, Imke AU - Grimmelmann I AD - Department of Dermatology, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany. FAU - Gutzmer, Ralf AU - Gutzmer R AD - Department of Dermatology, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany. AD - Department of Dermatology, Skin Cancer Center Minden, Johannes-Wesling-Klinikum Minden/Ruhr-University, Bochum, Minden, Germany. FAU - Schlaak, Max AU - Schlaak M AD - Department of Dermatology and Allergy, University Hospital of Munich (LMU), Munich, Germany. AD - Department of Dermatology, Venereology and Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Heppt, Markus V AU - Heppt MV AUID- ORCID: 0000-0003-4603-1825 AD - Department of Dermatology, Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), Universitatsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany. FAU - Ducker, Pia AU - Ducker P AD - Department of Dermatology, Hospital of Dortmund, Dortmund, Germany. FAU - Huning, Svea AU - Huning S AD - Department of Dermatology, Hospital of Dortmund, Dortmund, Germany. FAU - Schulmeyer, Lena AU - Schulmeyer L AD - Department of Dermatology, Venereology and Allergology, University Hospital Wurzburg, Wurzburg, Germany. FAU - Schilling, Bastian AU - Schilling B AUID- ORCID: 0000-0001-8859-4103 AD - Department of Dermatology, Venereology and Allergology, University Hospital Wurzburg, Wurzburg, Germany. FAU - Haferkamp, Sebastian AU - Haferkamp S AD - Department of Dermatology, University Hospital Regensburg, Regensburg, Germany. FAU - Ziemer, Mirjana AU - Ziemer M AUID- ORCID: 0000-0001-6488-1917 AD - Department of Dermatology, Venereology and Allergology, University Medical Center Leipzig, Leipzig, Germany. FAU - Moritz, Rose K C AU - Moritz RKC AD - Department of Dermatology, Venereology and Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Department of Dermatology and Venereology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. FAU - Hagelstein, Victoria AU - Hagelstein V AD - Department of Dermatology, Allergology, and Venereology, University of Lubeck, Lubeck, Germany. FAU - Terheyden, Patrick AU - Terheyden P AD - Department of Dermatology, Allergology, and Venereology, University of Lubeck, Lubeck, Germany. FAU - Posch, Christian AU - Posch C AUID- ORCID: 0000-0003-0296-3567 AD - Department of Dermatology, Venereology and Allergology, Clinic Hietzing, Vienna Healthcare Group, Vienna, Austria. AD - Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, Munich, Germany. AD - Faculty of Medicine, Sigmund Freud University Vienna, Vienna, Austria. FAU - Gaiser, Maria R AU - Gaiser MR AD - Department of Dermatology, Venerology and Allergology, Medical Faculty Mannheim, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany. AD - Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Kropp, Peter AU - Kropp P AD - Institute of Medical Psychology and Medical Sociology, University Medical Center Rostock, Rostock, Germany. FAU - Emmert, Steffen AU - Emmert S AD - Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany. FAU - Muller, Britta AU - Muller B AD - Institute of Medical Psychology and Medical Sociology, University Medical Center Rostock, Rostock, Germany. FAU - Tietze, Julia K AU - Tietze JK AUID- ORCID: 0000-0002-3351-8266 AD - Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany. LA - eng GR - EM 63/13-1/Deutsche Forschungsgemeinschaft/ GR - GRK2099/Deutsche Forschungsgemeinschaft/ GR - Forschungsforderung der Universitatsmedizin Rostock (FORUN)/ GR - Hiege Foundation-the German Skin Cancer Foundation/ PT - Journal Article PT - Multicenter Study DEP - 20221207 PL - England TA - J Eur Acad Dermatol Venereol JT - Journal of the European Academy of Dermatology and Venereology : JEADV JID - 9216037 RN - 0 (Immune Checkpoint Inhibitors) SB - IM CIN - J Eur Acad Dermatol Venereol. 2023 May;37(5):853-854. PMID: 37052422 MH - Humans MH - Quality of Life MH - Immune Checkpoint Inhibitors/therapeutic use MH - Cross-Sectional Studies MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - *Melanoma/pathology MH - *Skin Neoplasms/pathology EDAT- 2022/11/27 06:00 MHDA- 2023/04/17 06:41 CRDT- 2022/11/26 02:32 PHST- 2022/05/03 00:00 [received] PHST- 2022/11/08 00:00 [accepted] PHST- 2023/04/17 06:41 [medline] PHST- 2022/11/27 06:00 [pubmed] PHST- 2022/11/26 02:32 [entrez] AID - 10.1111/jdv.18778 [doi] PST - ppublish SO - J Eur Acad Dermatol Venereol. 2023 May;37(5):884-893. doi: 10.1111/jdv.18778. Epub 2022 Dec 7.